2-Chloro-6-(piperazin-1-yl)pyrazine hydrochloride

Catalog No. :
ACTCOM953
CAS No. :
61655-58-1
Molecular Formula :
C8H12Cl2N4
Molecular Weight :
235.12

IUPAC Name:2-chloro-6-(piperazin-1-yl)pyrazine hydrochloride

2-Chloro-6-(piperazin-1-yl)pyrazine hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$54.00Login to see priceIn stockInquiry
100mg98%$65.00Login to see priceIn stockInquiry
250mg98%$78.00Login to see priceIn stockInquiry
1g98%$190.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Chloro-6-(piperazin-1-yl)pyrazine hydrochloride
IUPAC Name2-chloro-6-(piperazin-1-yl)pyrazine hydrochloride
MDL No.MFCD00673963
Molecular FormulaC8H12Cl2N4
Molecular Weight235.12
SMILESClC1=NC(N2CCNCC2)=CN=C1.[H]Cl
InChI KeyPFIZGLUIYAZQFU-UHFFFAOYSA-N
SynonymMK-212 HCl | T0294 | Q27269784 | PFIZGLUIYAZQFU-UHFFFAOYSA-N | DTXSID60210668 | PYRAZINE, 2-CHLORO-6-(1-PIPERAZINYL)-, HYDROCHLORIDE (1:1) | FT-0759415 | CS-0021156 | 2-Chloro-6-(1-piperazinyl)pyrazine monohydrochloride | MK-212 (monohydrochloride) | MK21
CAS No.61655-58-1
PubChem CID198421

Safety Data

Pictogram
Toxic
Signal Word
Danger
Hazard Statement(s)
H301
Precautionary Statement(s)
P301+P310

Synthetic Route by SureRoute

1. ACTCOM953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACOHLT304 route compound structure diagram
    ACOHLT3044774-14-5 In Stock
  4. Then
  5. ACTCOM953 route product structure diagram
    ACTCOM95361655-58-1 In Stock
Inquiry

2. ACTCOM953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEPKA241 route compound structure diagram
    ACEPKA241426829-52-9 In Stock
  2. Then
  3. ACTCOM953 route product structure diagram
    ACTCOM95361655-58-1 In Stock
Inquiry

Comments (0)